Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
QDEL · Nasdaq · United States · In Vitro & In Vivo Diagnostic Substances
In shortQuidelOrtho Corp is loss-making, burns cash and carries moderate debt, with revenue stable (−1.9% last year).
Financial health
Weak
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | -33.7% | 0/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | -41.5% | 0/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | -46.1% | 0/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | -15.9% | 0/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 1.50× | 58/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 1.38× | 34/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | – | n/a |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | -5.18× | 0/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | -0.56 | 0/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | -3.0% | 8/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | – | n/a |
| Years with positive free cash flow (last 5) | 3 of 5 | 50/100 |
Weight in the score: 20%
| Profitable years (last 5) | 2 of 5 | 40/100 |
|---|---|---|
| Years of revenue decline (last 5) | 3 of 5 | 0/100 |
| Revenue growth volatility | 43.2% | 0/100 |
| Operating margin volatility | 48.9% | 0/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | -5.8% | 0/100 |
|---|---|---|
| EPS growth, 3-year average | – | n/a |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
1 older year available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY22 | FY23 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 1,699 | 3,266 | 2,998 | 2,783 | 2,730 |
| Research & development | 96 | 188 | 245 | 219 | 186 |
| Selling, general & admin | 240 | 621 | 763 | 767 | 746 |
| Operating income | 906 | 844 | 139 | (1,961) | (919) |
| Interest expense | – | 76 | 148 | 164 | 178 |
| Pre-tax income | 900 | 736 | (29) | (2,132) | (1,108) |
| Income tax | 196 | 187 | (19) | (80) | 24 |
| Net income | 704 | 549 | (10) | (2,052) | (1,132) |
| Diluted EPS | $16.43 | $9.56 | −$0.15 | −$30.54 | −$16.69 |
| Diluted shares (millions) | 43 | 57 | 67 | 67 | 68 |
1 older year available with the 10-year history. Essential plan, from €8.25/month →
The last 8 reported quarters (10-Q and 10-K filings), in USD millions. The fourth quarter is derived from the annual report.
The last 8 quarters of QuidelOrtho Corp are included in the Investor plan. Try free for 7 days →
−0.56 Distress zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
5/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Jun 28, 2026 · Data updated Aug 7, 2026